Posted on by admin

Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal

Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal
The Key Non-Alcoholic Steatohepatitis Companies: Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharmaceuticals, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Madrigal Pharmaceuticals, GlaxoSmithKline, 89bio, Inc., Akero Therapeutics, Inc, Regeneron Pharmaceuticals, and others.

 

DelveInsight’s “Non-Alcoholic Steatohepatitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Non-Alcoholic Steatohepatitis, historical and forecasted epidemiology as well as the Non-Alcoholic Steatohepatitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Non-Alcoholic Steatohepatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Alcoholic Steatohepatitis Market Forecast

 

Some of the key facts of the Non-Alcoholic Steatohepatitis Market Report: 

  • Among the 7MM countries Non-Alcoholic Steatohepatitis market size was valued approximately USD 1,634 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In July 2024, Inventiva has provided updates on its Phase III NATiV3 clinical program evaluating lanifibranor for the treatment of metabolic dysfunction-associated steatohepatitis/non-alcoholic steatohepatitis (MASH/NASH). The recruitment process for the trial is currently ongoing at 347 sites in 19 countries.

  • DelveInsight’s analysis in 2022 indicated approximately 41,885,455 prevalent cases of Non-Alcoholic Steatohepatitis (NASH) across the 7MM (Seven Major Markets). Among them, 15,620,949 cases were diagnosed. These figures are expected to rise by 2032 across the 7MM.

  • In 2022, the United States reported the highest number of diagnosed prevalent cases of Non-Alcoholic Steatohepatitis (NASH), totaling 9,389,584 cases. In comparison, the EU4 countries and the UK had 3,674,346 cases, and Japan had 2,557,019 cases.

  • In the European region, Germany reported the highest diagnosed prevalence of Non-Alcoholic Steatohepatitis (NASH) with 965,439 cases, followed by Italy with 783,811 cases in 2022. Conversely, Spain had the lowest diagnosed prevalent population among the EU4 countries and the UK, with 549,113 cases.

  • The existing pipeline for Non-Alcoholic Steatohepatitis (NASH) comprises a diverse array of medications. Notable classes include FXR Agonists, FGF21 Stimulants, FGF19 Analog, Glucagon-like Peptide-1 (GLP-1) Agonist, Peroxisome Proliferator-activated Receptor (PPAR) Regulator, THR-β Agonist, and others. Ongoing research and ongoing clinical trials hold the promise of reshaping the market landscape for NASH treatment.

  • Key Non-Alcoholic Steatohepatitis Companies: Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharmaceuticals, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Altimmune, Inc., AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Madrigal Pharmaceuticals, GlaxoSmithKline, 89bio, Inc., Akero Therapeutics, Inc, Regeneron Pharmaceuticals, Hepagene (Shanghai) Co., Ltd., Inventiva Pharma, Hanmi Pharmaceutical, Madrigal Pharmaceuticals, Inc., Sinew Pharma Inc., Boston Pharmaceuticals, and others

  • Key Non-Alcoholic Steatohepatitis Therapies: Lanifibranor, Saroglitazar Magnesium, Semaglutide, VK2809, MGL-3196, HPG1860, Vonafexor (EYP001), Belapectin, Pegozafermin, Efruxifermin (EFX), DA-1241, NNC0194, J2H-1702, HSK31679, Pemvidutide, AZD9550, Survodutide, Namodenoson, Resmetirom, GSK4532990, BIO89-100, EFX, ALN-HSD, HPG1860, IVA337, HM15211, MGL-3196, SNP-610, BOS-580, and others

  • The Non-Alcoholic Steatohepatitis epidemiology based on gender analyzed that males have a slightly higher likelihood of being affected by NASH compared to females in the 7MM.

  • The Non-Alcoholic Steatohepatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Alcoholic Steatohepatitis pipeline products will significantly revolutionize the Non-Alcoholic Steatohepatitis market dynamics.

 

Non-Alcoholic Steatohepatitis Overview

Non-Alcoholic Steatohepatitis (NASH) is a liver condition characterized by the accumulation of fat in the liver, inflammation, and liver cell damage, resembling alcoholic liver disease but occurring in individuals who consume little to no alcohol. NASH is considered a severe form of non-alcoholic fatty liver disease (NAFLD) and can lead to complications such as cirrhosis, liver failure, and hepatocellular carcinoma (liver cancer).

 

Get a Free sample for the Non-Alcoholic Steatohepatitis Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market

 

Non-Alcoholic Steatohepatitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Non-Alcoholic Steatohepatitis Epidemiology Segmentation:

The Non-Alcoholic Steatohepatitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Non-Alcoholic Steatohepatitis

  • Prevalent Cases of Non-Alcoholic Steatohepatitis by severity

  • Gender-specific Prevalence of Non-Alcoholic Steatohepatitis

  • Diagnosed Cases of Episodic and Chronic Non-Alcoholic Steatohepatitis

 

Download the report to understand which factors are driving Non-Alcoholic Steatohepatitis epidemiology trends @ Non-Alcoholic Steatohepatitis Epidemiology Forecast

 

Non-Alcoholic Steatohepatitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Alcoholic Steatohepatitis market or expected to get launched during the study period. The analysis covers Non-Alcoholic Steatohepatitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non-Alcoholic Steatohepatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Non-Alcoholic Steatohepatitis Therapies and Key Companies

  • Lanifibranor: Inventiva Pharma

  • Saroglitazar Magnesium: Zydus Therapeutics

  • Semaglutide: Novo Nordisk A/S

  • VK2809: Viking Therapeutics

  • MGL-3196: Madrigal Pharmaceuticals, Inc

  • HPG1860: Hepagene

  • Vonafexor (EYP001): Enyo Pharma

  • Belapectin: Galectin Therapeutics Inc.

  • Pegozafermin: 89bio, Inc.

  • Efruxifermin (EFX): Akero Therapeutics, Inc

  • DA-1241: NeuroBo Pharmaceuticals Inc

  • NNC0194: Novo Nordisk A/S

  • J2H-1702: J2H Biotech

  • HSK31679: Haisco Pharmaceutical

  • Pemvidutide: Altimmune, Inc.

  • AZD9550: AstraZeneca

  • Survodutide: Boehringer Ingelheim

  • Namodenoson: Can-Fite BioPharma

  • Resmetirom: Madrigal Pharmaceuticals

  • GSK4532990: GlaxoSmithKline

  • BIO89-100: 89bio, Inc.

  • EFX: Akero Therapeutics, Inc

  • ALN-HSD: Regeneron Pharmaceuticals

  • HPG1860: Hepagene (Shanghai) Co., Ltd.

  • IVA337: Inventiva Pharma

  • HM15211: Hanmi Pharmaceutical

  • VK2809: Viking Therapeutics, Inc.

  • MGL-3196: Madrigal Pharmaceuticals, Inc.

  • SNP-610: Sinew Pharma Inc.

  • BOS-580: Boston Pharmaceuticals

 

Discover more about therapies set to grab major Non-Alcoholic Steatohepatitis market share @ Non-Alcoholic Steatohepatitis Treatment Landscape 

 

Non-Alcoholic Steatohepatitis Market Strengths

  • Growing research activities and multiple clinical trials ongoing for NASH, suggests that the number of drugs is being developed that will strengthen the market.

 

Non-Alcoholic Steatohepatitis Market Opportunities

  • The large pool of patients suffering from NASH and lucrative opportunities for market growth create attractive prospects for key players to work in these areas

 

Scope of the Non-Alcoholic Steatohepatitis Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Non-Alcoholic Steatohepatitis Companies: Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal Pharmaceuticals, Inc, Hepagene, Enyo Pharma, Galectin Therapeutics Inc., 89bio, Inc., Akero Therapeutics, Inc, NeuroBo Pharmaceuticals Inc, Novo Nordisk A/S, J2H Biotech, Haisco Pharmaceutical, Altimmune, Inc., AstraZeneca, Boehringer Ingelheim, Can-Fite BioPharma, Madrigal Pharmaceuticals, GlaxoSmithKline, 89bio, Inc., Akero Therapeutics, Inc, Regeneron Pharmaceuticals, Hepagene (Shanghai) Co., Ltd., Inventiva Pharma, Hanmi Pharmaceutical, Madrigal Pharmaceuticals, Inc., Sinew Pharma Inc., Boston Pharmaceuticals, and others

  • Key Non-Alcoholic Steatohepatitis Therapies: Lanifibranor, Saroglitazar Magnesium, Semaglutide, VK2809, MGL-3196, HPG1860, Vonafexor (EYP001), Belapectin, Pegozafermin, Efruxifermin (EFX), DA-1241, NNC0194, J2H-1702, HSK31679, Pemvidutide, AZD9550, Survodutide, Namodenoson, Resmetirom, GSK4532990, BIO89-100, EFX, ALN-HSD, HPG1860, IVA337, HM15211, MGL-3196, SNP-610, BOS-580, and others

  • Non-Alcoholic Steatohepatitis Therapeutic Assessment: Non-Alcoholic Steatohepatitis current marketed and Non-Alcoholic Steatohepatitis emerging therapies

  • Non-Alcoholic Steatohepatitis Market Dynamics: Non-Alcoholic Steatohepatitis market drivers and Non-Alcoholic Steatohepatitis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Non-Alcoholic Steatohepatitis Unmet Needs, KOL’s views, Analyst’s views, Non-Alcoholic Steatohepatitis Market Access and Reimbursement 

 

To know more about Non-Alcoholic Steatohepatitis companies working in the treatment market, visit @ Non-Alcoholic Steatohepatitis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Non-Alcoholic Steatohepatitis Market Report Introduction

2. Executive Summary for Non-Alcoholic Steatohepatitis

3. SWOT analysis of Non-Alcoholic Steatohepatitis

4. Non-Alcoholic Steatohepatitis Patient Share (%) Overview at a Glance

5. Non-Alcoholic Steatohepatitis Market Overview at a Glance

6. Non-Alcoholic Steatohepatitis Disease Background and Overview

7. Non-Alcoholic Steatohepatitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Non-Alcoholic Steatohepatitis 

9. Non-Alcoholic Steatohepatitis Current Treatment and Medical Practices

10. Non-Alcoholic Steatohepatitis Unmet Needs

11. Non-Alcoholic Steatohepatitis Emerging Therapies

12. Non-Alcoholic Steatohepatitis Market Outlook

13. Country-Wise Non-Alcoholic Steatohepatitis Market Analysis (2019–2032)

14. Non-Alcoholic Steatohepatitis Market Access and Reimbursement of Therapies

15. Non-Alcoholic Steatohepatitis Market Drivers

16. Non-Alcoholic Steatohepatitis Market Barriers

17.  Non-Alcoholic Steatohepatitis Appendix

18. Non-Alcoholic Steatohepatitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/